OverviewSuggest Edit

Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine. The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability. Valneva’s portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese encephalitis (IXIARO®) and the second (DUKORAL®) indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant). Valneva is incorporated in Lyon, France, listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Scotland and Sweden with approximately 400 employees.
TypePublic
HQSaint-Herblain, FR
Websitevalneva.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Sept 2020)17,401(-8%)
Share Price (Sept 2020)€6.6
Cybersecurity ratingDMore

Key People/Management at Valneva

Thomas Lingelbach

Thomas Lingelbach

President & Chief Executive Officer
Franck Grimaud

Franck Grimaud

President & Chief Business Officer
Frederic Jacotot

Frederic Jacotot

General Counsel and Corporate Secretary
David Lawrence

David Lawrence

Chief Financial Officer
Wolfgang Bender

Wolfgang Bender

Chief Medical Officer
Show more

Valneva Office Locations

Valneva has offices in Saint-Herblain, Lyon, Gaithersburg, Wien and in 4 other locations
Saint-Herblain, FR (HQ)
6 Rue Alain Bombard
Lyon, FR
12 Quai Perrache batiment a
Lyon, FR
70, rue Saint Jean de Dieu
Wien, AT
Campus-Vienna-Biocenter 3
Kirkland, CA
3535 Boulevard Saint-Charles #600
Solna, SE
Gunnar Asplunds allé 16
Show all (9)

Valneva Financials and Metrics

Valneva Revenue

Market capitalization (23-Sept-2020)

603.7m

Closing stock price (23-Sept-2020)

6.6
Valneva's current market capitalization is €603.7 m.
Show all financial metrics

Valneva Cybersecurity Score

Cybersecurity ratingPremium dataset

D

67/100

SecurityScorecard logo

Valneva Online and Social Media Presence

Embed Graph

Valneva News and Updates

Valneva Announces Retirement of Chief Financial Officer David Lawrence

 Saint-Herblain (France), September 18, 2020 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced the retirement of its Chief Financial Officer, David Lawrence, at the end of 2020.

UK signs €1.4bn deal for Valneva coronavirus vaccine

The UK government has inked a €1.4bn (£1.3bn) deal to secure up to 190m doses of a coronavirus vaccine being The post UK signs €1.4bn deal for Valneva coronavirus vaccine appeared first on CityAM.

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

· UK Government has secured supply of 60 million doses at a cost of €470 million with options over another 130 million doses between 2022 and 2025

Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine

SAINT-HERBLAIN, France and EMERYVILLE, Calif., Sept. 14, 2020 /PRNewswire/ -- Valneva SE ("Valneva"), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on...

Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553

First Chikungunya Vaccine Candidate to Enter Phase 3 Clinical Development

Valneva Announces Appointment of Juan Carlos Jaramillo as Chief Medical Officer

Saint-Herblain (France), August 6, 2020 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced the appointment of Juan Carlos Jaramillo, MD as Chief Medical Officer and member of the Management Board starting 1st October 2020. …
Show more

Valneva Blogs

Valneva Announces its Intention to Delist from the Vienna Stock Exchange

Valneva Announces its Intention to Delist from the Vienna Stock Exchange Trading will be centralized on Euronext Paris Saint-Herblain (France), January 7, 2019 Valneva SE (“Valneva”), a biotech company developing and commercializing vaccines for in

Valneva Initiates Phase 2 Clinical Development for its Lyme Disease Vaccine Candidate

Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate Saint-Herblain (France), December 17, 2018 Valneva SE (“Valneva”), a biotech company developing and commercializing vaccines for infectious diseases with major un

Valneva to Conduct Investor and Partnering Meetings During the 37th Annual J.P. Morgan Healthcare Conference

Valneva to Conduct Investor and Partnering Meetings During the 37th Annual J.P. Morgan Healthcare Conference Saint-Herblain (France), December 4, 2018 Valneva SE (“Valneva”), a biotech company developing and commercializing vaccines for infectious

Emergent BioSolutions and Valneva Report Positive Phase 1 Results for their Vaccine Candidate Against the Zika Virus

Emergent BioSolutions and Valneva Report Positive Phase 1 Results for their Vaccine Candidate Against the Zika Virus GAITHERSBURG, Md. and Saint-Herblain, France, November 19, 2018 - Emergent BioSolutions Inc. (NYSE: EBS) and Valneva SE (VLA) today a

Valneva Receives Positive Feedback from EMA on its further Development for Lyme Disease Vaccine VLA15

Valneva Receives Positive Feedback from EMA on its further Development for Lyme Disease Vaccine VLA15 Saint Herblain (France), October 25, 2018 Valneva SE (“Valneva” or “the Company”), a commercial stage biotech company focused on developing innova
Show more

Valneva Frequently Asked Questions

  • Who are Valneva key executives?

    Valneva's key executives are Thomas Lingelbach, Franck Grimaud and Frederic Jacotot.

  • How many employees does Valneva have?

    Valneva has 17,401 employees.

  • Who are Valneva competitors?

    Competitors of Valneva include Therapeutic Solutions International, Twist Bioscience and Diffusion Pharmaceuticals.

  • Where is Valneva headquarters?

    Valneva headquarters is located at 6 Rue Alain Bombard, Saint-Herblain.

  • Where are Valneva offices?

    Valneva has offices in Saint-Herblain, Lyon, Gaithersburg, Wien and in 4 other locations.

  • How many offices does Valneva have?

    Valneva has 9 offices.